Ioflupane

Small molecule

WWeill Medical College of Cornell University

Ioflupane is one of 8 small molecule programs targeting REM sleep behavior disorder. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

REM Sleep Behavior DisorderActive, not recruiting

REM Sleep Behavior DisorderPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in REM Sleep Behavior Disorder

#DrugCompanyPhaseTrials

Rozerem

Takeda

Approved

1 2

Xyrem

Jazz Pharmaceuticals

Approved

1 3

Hetlioz

VVanda Pharmaceuticals

Approved

—4

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 5

Humira

CCelltrion

Phase 2

1 6

Nelotanserin

AAxovant Sciences Ltd.

Phase 2

2 7

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

—8

Ioflupane

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

REM sleep behavior disorder1 trial

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT03675282·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ioflupane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ioflupane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ioflupane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: WWeill Medical College of Cornell University

Ioflupane

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

REM sleep behavior disorder1 trial

References

Drug Info

Quick Facts

Related News